title: Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein.
abstract: The lack of an appropriate in vitro infection system for the major human pathogen hepatitis B virus (HBV) has prevented a molecular understanding of the early infection events of HBV. We used the novel HBV-infectible cell line HepaRG and primary human hepatocytes to investigate the interference of infection by HBV envelope protein-derived peptides. We found that a peptide consisting of the authentically myristoylated N-terminal 47 amino acids of the pre-S1 domain of the large viral envelope protein (L protein) specifically prevented HBV infection, with a 50% inhibitory concentration (IC50) of 8 nM. The replacement of myristic acid with other hydrophobic moieties resulted in changes in the inhibitory activity, most notably by a decrease in the IC50 to picomolar concentrations for longer unbranched fatty acids. The obstruction of HepaRG cell susceptibility to HBV infection after short preincubation times with the peptides suggested that the peptides efficiently target and inactivate a receptor at the hepatocyte surface. Our data both shed light on the molecular mechanism of HBV entry into hepatocytes and provide a basis for the development of potent hepadnaviral entry inhibitors as a novel therapeutic concept for the treatment of hepatitis Beta.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale (INSERM) U522, Hôpital de Pontchaillou, Rennes, France,
authors.forename: Philippe
authors.initials: P
authors.lastname: Gripon
authors.forename: Isabelle
authors.initials: I
authors.lastname: Cannie
authors.forename: Stephan
authors.initials: S
authors.lastname: Urban
mesh_terms: D000595:Amino Acid Sequence; D002460:Cell Line; D002478:Cells, Cultured; D000939:Epitopes / Q000737:chemistry; D006510:Hepatitis B Antibodies / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D006515:Hepatitis B virus / Q000187:drug effects* / Q000472:pathogenicity*; D022781:Hepatocytes / Q000821:virology; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation; D019814:Myristic Acid / Q000378:metabolism; D009500:Neutralization Tests; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D011498:Protein Precursors / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D011991:Receptors, Virus / Q000378:metabolism
chemical_list: D000939:Epitopes; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D010455:Peptides; D011498:Protein Precursors; D011991:Receptors, Virus; C050806:presurface protein 1, hepatitis B surface antigen; D019814:Myristic Acid